⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
FSTL3 in Ovarian Aging / POI
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-08-28 — Identifying novel druggable targets and repurposable drugs for premature ovarian insufficiency by integrated multiomics and causal inference analysis.: Multi-cohort proteomic MR flagged FSTL3 as a high-confidence causal POI target; dysregulation confirmed in cisplatin-induced granulosa-cell models with high diagnostic AUC, but no interventional or clinical readout. [human-observational] (novelty: 3)
Open questions
Related
Contributing findings
Identifying novel druggable targets and repurposable drugs for premature ovarian insufficiency by integrated multiomics and causal inference analysis.
28-aug-2026
novelty 3
per-area 3
strengthens